Progression-Free Survival Endpoint Not Reached in Abituzumab Study
the Cancer Therapy Advisor take:
According to a new study published in the Annals of Oncology, the randomized phase 1/2 POSEIDON trial investigating the use of abituzumab combined with cetuximab and irinotecan for the treatment of patients with KRAS wild-type metastatic colorectal cancer did not meet its primary progression-free survival endpoint.
For the study, researchers sought to investigate abituzumab, a humanized monoclonal antibody that targets intregrins involved in tumor progression and metastasis. Patients with KRAS wild-type metastatic colorectal cancer who had progressed after oxaliplatin-containing therapy were randomly assigned to receive abituzumab 500mg every 2 weeks with cetuximab and irinotecan (arm A), abituzumab 1000mg every 2 weeks with cetuximab and irinotecan (arm B), or cetuximab and irinotecan alone (arm C).
The phase 1 portion of the study demonstrated abituzumab was safe at doses up to 1000mg. Results showed similar progression-free survival rates among all three arms in the phase 2 part.
The hazard ratio of arm A versus arm C was 1.13 (95% CI 0.78 - 1.64) and the hazard ratio of arm B compared with arm C was 1.11 (95% CI 0.77 - 1.61). Results showed similar response rates among all three arms, but researchers note that there was a trend toward improved overall survival in patients treated with abituzumab.
Abituzumab with cetuximab and irinotecan forcolorectal cancer did not meet primary endpoint.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer